Forman Mark S 4
4 · Passage BIO, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
Forman Mark S
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-01-02$0.91/sh−15,813$14,390→ 45,269 total - Exercise/Conversion
Common Stock
2023-12-31+50,000→ 61,082 total - Exercise/Conversion
Restricted Stock Unit
2023-12-31−50,000→ 0 total→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
- [F3]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F4]Each RSU represents a contingent right to receive one share of Issuer's common stock.
- [F5]100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.